Covid-19 is shedding further light on pharmaceutical sourcing strategies and their inherent complexity. Consider the example of Gilead’s ramp-up of remdesivir manufacture under FDA Emergency Use Authorization. Behind the scenes, Gilead is managing the production of an API in Canada, sourcing key starting materials from across the globe, and finishing the injectable product at a facility in La Verne, CA. The enormity of the task when the product is early in its lifecycle is substantial. And, consider the efforts of so many companies racing to bring vaccines and therapeutics for Covid-19 through clinical development, demonstrating safety and efficacy at speeds rarely seen in the past.

To read more, please download this free white paper.